The world is waiting for Moderna’s COVID-19 vaccine results, but meanwhile the company is exploring new avenues to secure long-term growth
Moderna, Inc. may be engaged in a once-in-a-biotech’s-lifetime challenge to develop a COVID-19 vaccine, but that does not mean it is not looking ahead to other opportunities.
The company signed two early stage deals on 16 September which together generate $100m upfront revenues - one an expansion...
The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
The company’s oral GLP-1 candidate has reassured on its safety at the American Diabetes Association meeting, convincing analysts it will open up new global markets.
